

Corona alternating current electrospinning: A combined approach for increasing the productivity of electrospinning

Farkas B., Balogh A., Cselko R., Molnár K., Farkas A., Borbas E., Marosi Gy., Nagy Z. K.

This accepted author manuscript is copyrighted and published by Elsevier. It is posted here by agreement between Elsevier and MTA. The definitive version of the text was subsequently published in [International Journal of Pharmaceutics, 561, 2019, DOI: [10.1016/j.ijpharm.2019.03.005](https://doi.org/10.1016/j.ijpharm.2019.03.005)]. Available under license CC-BY-NC-ND.

1 **Corona Alternating Current Electrospinning: A combined approach for**
2 **increasing the productivity of electrospinning**

3 Balázs Farkas^a, Attila Balogh^{a,*}, Richárd Cselkó^b, Kolos Molnár^{c,d}, Attila Farkas^a, Enikő
4 Borbás^a, György Marosi^a, Zsombor Kristóf Nagy^a

5 ^a*Budapest University of Technology and Economics, Department of Organic Chemistry and*
6 *Technology, H-1111 Budapest, Hungary*

7 ^b*Budapest University of Technology and Economics, Department of Electric Power*
8 *Engineering, H-1111 Budapest, Hungary*

9 ^c*Budapest University of Technology and Economics, Department of Polymer Engineering,*
10 *H-1111 Budapest, Hungary*

11 ^d*MTA–BME Research Group for Composite Science and Technology, H-1111 Budapest,*
12 *Hungary*

13
14 * *Corresponding author at: Hungary, 1111 Budapest, Budafoki út 8. E-mail address:*
15 *baloghattila5@gmail.com (A. Balogh)*

16
17 *Keywords: corona electrospinning, polyvinylpyrrolidone, oral drug delivery, nanotechnology,*
18 *dissolution enhancement, solution conductivity, scale-up*

19 **Abstract**

20 Corona alternating current electrospinning (C-ACES), a scaled-up productivity
21 electrospinning method was developed by combining the intense forces of the alternating
22 electrostatic field and a sharp-edged spinneret design with increased free surface. C-ACES
23 reached two orders of magnitude higher productivity (up to 1200 mL/h) than the classical single
24 needle direct current electrospinning (DCES) without any alteration of fiber properties.
25 Polyvinylpyrrolidone K90 (PVPK90), a water soluble high molecular weight nonionic polymer

26 was processed for the first time with single needle alternating current electrospinning (ACES)
27 and C-ACES in order to prepare fast dissolving amorphous solid dispersions of spironolactone
28 (SPIR), a poorly water-soluble antihypertensive model drug. The limited spinnability of
29 PVPK90 with AC high voltage could only be resolved by optimizing the solution conductivity
30 with organophilic salts such as sodium dodecyl sulfate (SDS) demonstrating the importance of
31 conductivity during ACES. The effects of varied solution properties (composition and
32 conductivity) and scaling-up were investigated by SEM imaging. Solid state analyses revealed
33 that SPIR was dispersed in an amorphous form in the fibrous mats. In vitro dissolution tests
34 showed ultrafast drug release in case of the amorphous formulations even when prepared with
35 scaled-up C-ACES. Besides the enhancement of conductivity SDS also prevents SPIR from
36 precipitation from the dissolution media due to its solubilization ability.

37 **1. Introduction**

38 The number of poorly water soluble drugs for the last decades has been growing in the
39 pharmaceutical industry. This phenomenon sets a great challenge for pharmaceutical
40 researchers since poor water solubility leads to low dissolution speed and therefore
41 unsatisfactory bioavailability levels. Therefore, the development of methods aiming to
42 overcome this hurdle is becoming more and more important (Kawabata et al., 2011,
43 Vasconcelos et al., 2007).

44

45 Dissolution properties can be enhanced by increasing the specific surface area and the
46 saturation solubility of the drug based on the Noyes-Whitney equation (Hörter and Dressman,
47 2001, Yu et al., 2018). For creating large surfaces particle size reduction methods such as
48 micronization and nanonization are applicable ways (Li et al., 2017). In addition, higher
49 dissolved drug concentration can be achieved by solubilizing the drug using surfactants or
50 complexing agents such as cyclodextrins (Borbás et al., 2015). Besides these approaches, the

51 amorphization of a drug by preparing amorphous solid dispersions (ASDs) allows much higher
52 drug concentration by reaching a supersaturated state (Yu et al., 2019, Zupančič et al., 2018a).
53 By forming a molecular dispersion of an active pharmaceutical ingredient (API) in a matrix
54 polymer, ASDs lead to an enhanced dissolution due to the higher energy state of the drug
55 amorphized this way (Škrlec et al., 2019). Moreover, it has been shown that not only the release
56 but the absorption is also assisted with ASDs due to the evolving supersaturated solution during
57 dissolution (Borbás et al., 2018, Frank et al., 2014). The number of marketed pharmaceuticals
58 based on ASDs has almost doubled in the last five years indicating the importance of these
59 methods (Jermain et al., 2018).

60

61 The combination of the amorphous form of the API and increased specific surface area
62 results in even better dissolution. Electrospinning (ES) has gained great attention due to the
63 ability to form large surface area fibrous ASDs from polymeric solutions and melts under the
64 drawing force of the electrostatic field (Balogh et al., 2018, Balogh et al., 2014, Hirsch et al.,
65 2018, Marosi et al., 2018, Zupančič et al., 2018b). Direct current electrospinning (DCES) is the
66 simplest and most common method for preparing electrospun ASDs with controlled drug
67 release (e.g., sustained (Angkawinitwong et al., 2017, Liu et al., 2018), targeted (Nagy et al.,
68 2013) or ultrafast release (Farkas et al., 2018, Nagy et al., 2010)). Despite these advantages the
69 productivity of DCES is quite low ($\sim 1\text{--}2$ g/h) for industrial applications (Lukáš et al., 2009).
70 The simplest attempt for the scale up was the introduction of multiple spinnerets, although it
71 turned out to be challenging due to the perpetual clogging of the spinning tips (Theron et al.,
72 2005). Therefore, needleless methods were developed to increase productivity such as free
73 surface ES (Persano et al., 2013). Even better results could be achieved with the combination
74 of the centrifugal force and the electrostatic field with a reported maximum of 1500 mL/h at
75 40,000 rpm (Kostakova et al., 2017, Nagy et al., 2015).

76

77 At corona ES the solution continuously exits a narrow, annular orifice (Molnar and
78 Nagy, 2016). The annulus is surrounded by a metal electrode having sharp edge from the
79 outside. The highest electrical charge density forms along the sharp edge (i.e., where the
80 solution is fed), which results in many Taylor-cones. The spinneret is rotated at moderate
81 angular velocity in order to homogeneously disperse the polymer solution along the annulus
82 and to prevent local overflows. Corona ES offers a much simpler mechanical design compared
83 to the high frequency versions and reaches a maximum productivity of 300 mL/h, thus, it could
84 offer a more desired choice for the scale up of electrospinning.

85

86 Novel alternating current electrospinning (ACES) also provides multiple times higher
87 productivities by simply replacing the direct current high voltage generator with an alternating
88 current power supply (Balogh et al., 2015a, Pokorny et al., 2014). During ACES multiple jets
89 are drawn from the droplet leaving the tip of the spinneret. As a result, a so-called nanofibrous
90 plume is generated from the polymeric solutions carried by the electric wind. Due to the
91 alternately charged plume the collection is implemented without a grounded surface making
92 the process simpler with similar fiber morphology compared to DCES. The productivity of
93 ACES could also be extended with the combination of the centrifugal force expecting even
94 higher throughputs compared to DC high voltage. However, ACES has never been connected
95 with a rotating-type spinneret so far.

96

97 Recent studies revealed that solution conductivity is an essential factor during ACES
98 besides the molecular weight of the applied polymer. Cellulose derivatives of low molecular
99 weight hydroxypropylmethylcellulose (HPMC 2910, $M_w = 20$ kDa) and
100 hydroxypropylmethylcellulose acetate succinate (HPMCAS LF, $M_w = 18$ kDa) were processed


101 with ACES for pharmaceutical uses (Balogh et al., 2017, Balogh et al., 2016). Both HPMC and
102 HPMCAS were found to be poorly electrospinnable regardless the type of the applied high
103 voltage. The addition of small amounts of polyethylene oxides as active fiber forming agents
104 resolved the issue of poor fibers with HPMC. In the case of HPMCAS the optimization of
105 solution conductivity was also required for defect-free AC electrospun fibers. For that purpose
106 SDS, NH₄OAc and CaCl₂ were suitable excipients and also well soluble in the used solvent
107 mixture (DCM-EtOH 1:1). A high molecular weight polymer never failing with DCES,
108 polyvinylpyrrolidone K90 (PVPK90) was also tested with ACES, but only low quality samples
109 could be obtained at higher feeding rates (Balogh et al., 2015a). Thus, the question arises
110 whether the optimization of solution conductivity would result in good quality fibrous mats
111 from PVPK90.

112

113 Accordingly, in this study we attempted to increase the productivity of ES with the
114 combination of ACES and the corona-type spinneret. Polyvinylpyrrolidone K90 (PVPK90)
115 was selected as fiber forming polymer considering that one third of the marketed ASDs are
116 based on polyvinylpyrrolidones. Relying on our earlier experiences the hurdle of poor ACES
117 electrospinnability of PVPK90 was attempted to be resolved by the optimization of solution
118 conductivity. Spironolactone (SPIR), an antihypertensive with limited water solubility
119 (28 µg/mL, (Nagy et al., 2012)) was chosen as the model drug. SPIR is known for being prone
120 to precipitation; this matter also had to be considered during formulation development. The
121 morphology of the fibrous samples was monitored with scanning electron microscopy (SEM).
122 The physical state of the drug was studied with differential scanning calorimetry (DSC), X-
123 ray powder diffraction (XRPD) and Raman mapping. In vitro dissolution tests were

124

performed in order to examine the characteristics of the drug release.



125

126 Figure 1. The corona electrospinning setup. 1) rotating spinneret, 2) high voltage
127 electrode, 3) inner part, 4) annular orifice with forming Taylor-cones, 5) forming fibers,
128 6) high voltage source, 7) solution feed, 8) distribution channel (Molnar et al. 2012)

129

130 2. Materials and methods

131 2.1. Materials

132 Polyvinylpyrrolidone K90 (PVPK90) with an average molecular weight of ~ 1000 kDa was
133 received from BASF (Ludwigshafen, Germany). Spironolactone (SPIR) from Sigma-Aldrich
134 (Budapest, Hungary) was used as API. Organic and inorganic salts of sodium dodecyl sulfate
135 (SDS), anhydrous calcium chloride (CaCl_2), and ammonium acetate (NH_4OAc) were obtained
136 from Sigma-Aldrich. Absolute ethanol (EtOH) and dichloromethane (DCM) were purchased
137 from Molar Chemicals (Budapest, Hungary). Direct current electrospinning (DCES)

138

139 2.2. Direct current electrospinning (DCES)

140 The DCES tests were conducted using an NT-35 high voltage direct current supply
141 (MA2000; Unitronik Ltd, Nagykanizsa, Hungary). The electrical potential applied on the

142 spinneret electrode was 25 kV in all cases. A grounded aluminum plate covered with aluminum
143 foil was used as collector. The distance of the spinneret and the collector was 20 cm. Solutions
144 of the polymeric excipient and the drug were prepared for electrospinning using a magnetic
145 stirrer (600 rpm). The solutions were dosed by a SEP-10S Plus type syringe pump through a
146 needle spinneret (1 mm ID, 2 mm OD) at 10 mL/h rate.

147 **2.3. Direct current corona electrospinning (C-DCES)**

148 The C-DCES tests were conducted using an NT-35 high voltage direct current supply
149 (MA2000; Unitronik Ltd, Nagykanizsa, Hungary). The electrical potential applied on the
150 spinneret electrode was 40 kV in all cases. A grounded aluminum plate covered with aluminum
151 foil was used as collector. The distance of the spinneret and the collector was 20 cm. Solutions
152 of the polymeric excipient and the drug were prepared for electrospinning similarly to that of
153 the DCES experiments. The solutions were dosed by a SEP-10S Plus type syringe pump
154 through a corona spinneret (110 mm OD) at 100-300 mL/h rate.

155 **2.4. Alternating current electrospinning (ACES)**

156 The ACES experiments were conducted using an FME-24 voltage transformer
157 (24,000 V/100 V ratio) (Transzvil Ltd, Budapest, Hungary) fed by a 0–230 V variable
158 transformer. The electrical potential applied on the spinneret electrode was 25 kV (root mean
159 square, RMS) at the frequency of the mains voltage (50 Hz). The sinusoidal AC high voltage
160 was controlled by manual feedback using the variable transformer based on the measured output
161 signal of a high voltage probe connected to the electrode. Solutions of the polymeric excipient
162 and the drug were prepared for electrospinning using a magnetic stirrer (600 rpm). The solutions
163 were dosed by a Harvard Apparatus Model 33 type twin syringe pump (Harvard Apparatus Inc.,
164 Holliston, Massachusetts, USA) through a needle spinneret (1 mm ID, 3 mm OD) at
165 predetermined flow rates. The flying fibers were collected in a basket fixed to an insulating
166 PVC rod positioned above the spinneret in 20–100 cm distances.

2.5. Corona alternating current electrospinning (C-ACES)

The corona alternating current electrospinning (C-ACES) experiments were performed with a rotating corona spinneret set to 100 rpm ((Molnar and Nagy, 2016), Fig. 4). The diameter of the annular orifice was 110 mm. The annulus was surrounded by a sharp-edged aluminum part from the outside and a polyamide part from the inside. The gap size (gap between these two parts, in which the solution leaves the spinneret) was 1 mm. The C-ACES experiments were conducted using a TUR PEO 8/100A voltage transformer (200/100,000 V ratio, VEB Transformatoren und Röntgenwerk Dresden) fed by a 0–230 V variable transformer. The electrical potential applied on the corona spinneret electrode was 100 kV (root mean square, RMS) at the frequency of the mains voltage (50 Hz). The sinusoidal AC high voltage was controlled by manual feedback using the variable transformer based on the measured output signal of a high voltage capacitive divider connected to the electrode. Polymeric solutions were prepared similarly to the ACES experiments, and the same Harvard Apparatus Model 33 type twin syringe pump was used for feeding the corona spinneret between 100 and 1500 mL/h rate. For safety precautions, both the syringe pump and the corona spinneret were operated from a 12 V battery and placed in a Faraday-cage. The collection of the fibers was aided with a grounded metal grid positioned 75 cm above the rotating spinneret.

2.6. Scanning electron microscopy (SEM) and fiber diameter analysis

Morphology of the samples was investigated by a JEOL 6380LVa (JEOL, Tokyo, Japan) type scanning electron microscope. Each specimen was fixed by conductive double-sided carbon adhesive tape and sputter coated with gold prior to the examination. Applied accelerating voltage and working distance were 15–30 kV and 10 mm, respectively. A randomized fiber diameter determination method was used based on scanning electron microscopy imaging as described in our previous work (Balogh et al., 2015b), n = 100 measurements were made on each sample.

192 **2.7. Differential scanning calorimetry (DSC)**

193 Differential scanning calorimetry measurements were carried out using a Setaram
194 (Calure, France) DSC 92 apparatus (sample weight: ~10–15 mg, open aluminum pan, nitrogen
195 flush). The temperature program consisted of an isothermal period, which lasted for 1 min at
196 25 °C, with subsequent linear heating from 25 °C to 250 °C at the rate of 10 °C/min. Purified
197 indium standard was used to calibrate the instrument.

198 **2.8. X-ray powder diffraction (XRPD)**

199 Powder X-ray diffraction patterns were recorded by a PANanalytical X'pert Pro MDP
200 X-ray diffractometer (Almelo, The Netherlands) using Cu-K α radiation (1.542 Å) and Ni filter.
201 The applied voltage was 40 kV while the current was 30 mA. The untreated materials, a physical
202 mixture composition and the fibrous samples as spun were analyzed for angles 2θ between 4°
203 and 42°.

204 **2.9. Raman mapping**

205 Raman mapping was carried out using a Horiba Jobin–Yvon LabRAM (Longjumeau,
206 France) system coupled with an external diode laser source (785 nm, 80 mW) and an Olympus
207 BX-40 optical microscope. The fibrous samples were gently compressed into a flat tablet
208 (Camilla OL95; Manfredi, Torino, Italy) and the spectra were recorded with an objective of
209 50 \times (NA = 0.5) magnification. The measured area was 100 \times 100 μm^2 with 5 μm step size in
210 both directions meaning that 441 spectra were gathered from each sample. The component
211 concentrations were estimated with the classical least squares (CLS) method using the reference
212 spectra of the pure components collected on the same device under the same conditions.
213 Visualized score maps were created with LabSpec 5.41 (Horiba Jobin–Yvon).

214 **2.10. *In vitro* dissolution measurement**

215 The dissolution studies were performed using a Pharmatest PTWS 600 dissolution tester
216 (USP II apparatus (paddle); Hainburg, Germany). Samples equivalent to 25 mg of SPIR were

217 added directly into the dissolution vessel containing 900 mL of dissolution liquid (pH = 6.8
 218 100 mM phosphate buffer prepared according to USP). Electrospun samples were used for
 219 dissolution tests as spun. The temperature was maintained at 37 ± 0.5 °C and stirred at 100 rpm.
 220 An on-line coupled Agilent 8453 UV–Vis spectrophotometer (Palo Alto, CA) was used to
 221 measure the concentration of dissolved SPIR at a wavelength of 244 nm. Percentage of
 222 dissolution was readily calculated according to the calibration curve of SPIR due to the lack of
 223 absorption peaks of the applied excipients in this range.

224

225 3. Results and discussion

226 3.1. Processing PVPK90 with ACES


227 PVPK90 is known to be well processable with DCES. It was no different in this case since fine PVPK90
 228 fibers could be electrospun from simple DCM-EtOH solutions at a throughput rate of 10 mL/h utmost. In
 229 contrast as described in the introductory part PVPK90 could not be processed with ACES at increased
 230 throughput rates (>10 mL/h) during an earlier study from simple ethanol-based solutions (Balogh et al.,
 231 2015a). To begin with, the optimization of polymer concentration and conductivity was performed in order
 232 to obtain AC electrospun PVPK90 nanofibers at elevated productivity. A 42 full factorial design of
 233 experiments (DoE) was carried out, the amount of PVPK90 and the solution conductivity were set on four
 234 levels (see Table 1 for exact values). SDS was selected to adjust conductivity as an organic salt well soluble
 235 in DCM-EtOH solvent mixtures. The concentration of SDS was exponentially increased so that its effect on
 236 fiber morphology could be investigated in a wider range. The concentration of PVPK90 was varied based
 237 on earlier experiments with pure ethanol (Balogh et al., 2015a, Vigh et al., 2013). The mixture of DCM-
 238 EtOH (50:50 vol/vol%) was used as it is able to dissolve both hydrophobic and hydrophilic components
 239 while high volatility aids fiber formation and minimizes residual solvent content.

240 Table 1. The 4² design table for solution compositions tested with ACES of PVPK90. The optimal
 241 composition is marked with **green**.


PVPK90-SDS compositions dissolved in 10 mL pure DCM-EtOH 1:1				
PVPK90	SDS and solution conductivity			
	7,5 mg (~34 μS/cm)	15 mg (~52 μS/cm)	30 mg (~75 μS/cm)	60 mg (~103 μS/cm)
250 mg	Mainly beads and droplets, few fibers	Mainly beads and droplets, few fibers	Mainly beads and droplets, few fibers	Mainly beads and droplets, few fibers

			Fig. 2a	
500 mg	Beads and droplets, more fibers	Beads and droplets, more fibers	Beads and droplets, more fibers Fig. 2b	Beads and droplets, more fibers
750 mg	Less beads and droplets, more fibers Fig. 2e	Less beads and droplets, more fibers Fig. 2f	No beads, no droplets, decent fibers Fig. 2c	More beads and droplets, poor fibers Fig. 2g
1,000 mg	More beads and droplets, poor fibers	More beads and droplets, poor fibers	More beads and droplets, poor fibers Fig. 2d	More beads and droplets, poor fibers

242 As it can be seen in Fig. 1, SDS is an effective conductivity enhancer since a 7-fold increase in
243 solution conductivity could be observed even when added in low concentrations ($\sim 34 \mu\text{S}/\text{cm}$
244 in the 7.5 mg/10 mL solution compared to the initial solution with no SDS ($\sim 5 \mu\text{S}/\text{cm}$)).
245 Concentrations over 60 mg/10 mL resulted in regressively increasing conductivity thereby also
246 approaching the solubility limit of SDS. This range of conductivity proved to be feasible during
247 earlier studies to examine the effect of solution conductivity on fiber morphology in case of
248 ACES (Balogh et al., 2017).



249
250 Figure 1. Conductivity as a function of dissolved SDS in 10 mL DCM-EtOH 1:1. The value of conductivity
251 was found to be independent from the concentration of dissolved PVPK90.



252
 253 **Figure 2. Scanning electron microscopic images of AC electrospun PVPK90 fibers as a function of (a-d)**
 254 **polymer concentration at fixed conductivity (optimal 75 μ S/cm) and (e-h) SDS concentration at fixed**
 255 **polymer concentration (optimal 750 mg/10 mL pure solvent). Images c and g show the same overall**
 256 **optimum. (DCM-EtOH 1:1, 25 kV_{RMS}, 60 mL/h)**

257
 258 The DoE study provided the following results: Beads and droplets appeared among the fibers
 259 spun at low polymer concentrations (250 mg or 500 mg PVPK90 in 10 mL DCM-EtOH 1:1)
 260 regardless the applied amount of SDS (Fig. 2a and b). However, with an increased conductivity
 261 the amount of beads and droplets notably reduced. Increasing the concentration of PVPK90 to
 262 750 mg/10 mL and setting SDS to 30 mg/10 mL (\sim 75 μ S/cm) resulted in bead- and droplet-
 263 free, excellent quality fibers (Fig. 2c and g) giving the optimal composition.




264
 12

265 **Figure 3. Comparison of AC electrospun PVPK90 samples (a) without SDS added in the solution and (b)**
266 **with SDS introduced in the solution (25 kV_{RMS}, 60 mL/h).**

267 The remarkable difference between the AC electrospun PVPK90 samples without and
268 with adjusting conductivity can be seen in [Fig. 3](#). Without adding SDS into the polymer solution
269 the ACES resulted in the spattering of the liquid with little amount of fibers formed making the
270 product practically non collectible ([Fig. 3a](#)). In comparison a loose, easily collectible fibrous
271 plume could be obtained when the solution conductivity was optimized with SDS ([Fig. 3b](#)).
272 That result provided satisfactory evidence to our primary hypothesis that the processability of
273 PVPK90 with ACES can be resolved simply with optimized conductivity and without the need
274 for other polymeric [excipients](#) such as PEO.

275 The determined optimal conductivity value ($\sim 75 \mu\text{S}/\text{cm}$) resembles with our earlier
276 findings with HPMCAS solutions indicating a more general correlation between solution
277 conductivity and AC electrospinnability ([Balogh et al., 2017](#)). Presumably, ionic additives aid
278 faster charge transfer rates when polarity changes periodically on the polymeric liquid, thus, at
279 an optimum conductivity value the full potential of ACES can be reached in terms of defect-
280 free fiber morphology and increased throughput rates. When either the polymer concentration
281 or the conductivity was increased any further from the optimum values the quality decreased as
282 it can be seen in [Fig. 2d](#) and [h](#). Adding the components over their optimum values larger droplets
283 appeared and the fibers thickened ([Fig. 2h](#)). It could be also observed that the fibrous samples
284 had become more brittle due to the contaminating particles with larger dimensions. Scaled up
285 productivity C-ACES experiments




286

287 **Figure 4. The schematic drawing of the C-ACES method with the corona spinneret (OD=110 mm) coupled**
 288 **with AC high voltage. The application of a grounded surface is also recommended for proper fiber**
 289 **formation (not shown here).**

290 After the optimization of the production of PVPK90 with ACES, scaled-up preparation of
 291 fibrous mats was attempted with C-DCES and the novel C-ACES method (Fig. 4). According
 292 to previous studies the application of a corona spinneret usually requires higher DC voltage
 293 (~40 kV) compared to a single needle spinneret (25 kV) (Molnar and Nagy, 2016). C-DCES
 294 could be operated at ten times higher throughput rate when processing the optimized PVPK90-
 295 SDS solution compared to single needle DCES without any alteration in fiber morphology (Fig.
 296 5a). However, the increase of feeding rate to 300 mL/h resulted in significantly deteriorated
 297 fiber morphology with large droplets among the fibers (Fig. 5b). Also at this throughput range
 298 a part of the solution splattered and drained into the overflow tray of the corona plate indicating
 299 that the maximum productivity in this case is around 100 mL/h.

300



301 **Figure 5. SEM images of C-DCES placebo fibers prepared at (a) 100 mL/h and (b) 300 mL/h (25 kV).**

302 For C-ACES a higher AC voltage of at least 75 kV_{RMS} was needed to promote fiber production.

303 In comparison, the single needle ACES method only requires high voltages above 10 kV_{RMS}.

304 Another notable aspect of using the corona spinneret with AC high voltage was the application

305 of a grounded surface in front of the spinneret to aid fiber formation. While ACES with a

306 needle- or rod-type spinneret operates readily without a grounded counterpole (known as

307 collectorless operation), during C-ACES without the grounded surface the fibrous plume was

308 flying too slowly and the fibers started to soak and stick to the cap of the spinneret.

309 The C-ACES experiments were executed at throughput rates gradually increased from

310 100 mL/h to 1200 mL/h by 100 units (Fig. 6). In the mentioned throughput range smooth fiber

311 formation could be observed. When increasing the flow rate to 600 mL/h (Fig. 6b) and further

312 to 1200 mL/h (Fig. 6c), the fibrous plume expanded and the formation of fibers became more

313 intense. Over 1200 mL/h the fibers started to get wet on the collector and the excess solution

314 spattered out of the plate of the spinneret. SEM revealed same C-ACES fiber quality as in case


315 of ACES since no droplets or bead-on-string structures were observable in the images (Fig. 2c

316 and Fig. 7). Increasing the high voltage over 100 kV_{RMS} did not result in any significant


317 improvement in either fiber quality or productivity. C-ACES comes close to the most

318 productive yet simple ES method with a 20-fold throughput increase compared to single needle

319 ACES (60 mL/h) and with two orders of magnitude higher productivity compared to single
320 needle DCES (~10 mL/h).



322 **Figure 6. Production of PVPK90 fibers with C-ACES at (a) 100 mL/h, (b) 600 mL/h and (c) 1,200 mL/h (100**
323 **kV_{RMS}, 75 cm spinneret-collector distance). 1 – Corona spinneret (110 mm OD); 2 – Fibrous plume**
324 **(highlighted); 3 – Grounded grid; 4 – Measuring capacitor; 5 – High voltage power supply.**




326 **Figure 7. SEM images of C-ACES placebo fibers prepared at (a) 100 mL/h and (b) 1,200 mL/h feeding rates**
327 **(100 kV_{RMS}).**

328 3.2. Preparing drug-loaded scaled up productivity C-ACES fibers

329 After the optimization of the composition, drug-loaded PVPK90 fibers with 20% SPIR content
330 (w/w) were attempted to prepare using these methods in order to enhance the [dissolution](#)
331 properties of SPIR. The high throughput rate of C-ACES could be maintained even in the
332 presence of the active substance. As it can be seen in [Fig. 8](#), excellent quality drug-loaded

333 PVPK90-SDS-SPIR fibers could be obtained with both ACES and C-ACES possessing large
334 surfaces thereby an enhanced drug dissolution is expected.



335
336 **Figure 8. PVPK90-based nanofibers with SPIR content prepared with (a) ACES (60 mL/h) and (b) C-ACES**
337 **(1,200 mL/h).**

338 3.3. Fiber diameter analysis


339 Fiber diameter analysis was carried out in order to investigate the effects of the preparation
340 methods and drug loading on fiber thickness. [Table 2](#) shows that the average diameters of the
341 placebo PVPK90 + 4%SDS fibers are similarly around 1 μm regardless the type of high voltage
342 or the spinneret used. The results with PVPK90 fibers without any other components show
343 negligible effect of SDS on the average fiber diameter. The multiple times higher throughput
344 of C-ACES and C-DCES did not result in thicker fibers either. In case of the AC electrospun
345 fibers with SDS and 20% SPIR content, the average diameter is about 20% thinner than that of
346 the placebo samples. This fiber thinning phenomenon has already occurred in previous cases
347 when SPIR was applied as active compound ([Balogh et al., 2017](#), [Balogh et al., 2016](#)). A
348 different conclusion could be drawn when SDS was replaced to CaCl_2 and NH_4OAc in ACES
349 fibers (see more in [Section 3.6](#)), in these cases the SPIR-loaded PVPK90 samples occurred to
350 be thicker than the placebo fibers if they contained NH_4OAc or CaCl_2 ([Fig. 9](#)). Thus, further

351 investigation is needed to fully explain the dependence of AC electrospun fiber diameter on the
 352 composition of the polymer solution.

353 **Table 2. Mean fiber diameters of DC (10 mL/h, 25 kV), C-DC (100 mL/h, 40 kV), AC (60 mL/h, 25 kV_{RMS})**
 354 **and C-AC (1,200 mL/h, 100 kV_{RMS}) electrospun PVPK90-based fibers with optimized amounts of salts (SDS,**
 355 **CaCl₂, NH₄OAc) with and without SPIR.**

Composition	Mean fiber diameter ($\mu\text{m} \pm \text{SD}$)			
	DCES (10 mL/h)	C-DCES (100 mL/h)	ACES (60mL/h)	C-ACES (1,200 mL/h)
PVPK90	0.88±0.27	0.92±0.27	poor fibers	poor fibers
PVPK90+4%SDS	0.93±0.35	0.87±0,39	1.14±0.46	1.07±0.55
PVPK90+4%SDS+20%SPIR	-	-	0.83±0.35	0.81±0.32
PVPK90+2.5%NH ₄ OAc	-	-	0.72±0.22	-
PVPK90+2.5%NH ₄ OAc+20%SPIR	-	-	1.07±0.45	-
PVPK90+0.5%CaCl ₂	-	-	1.00±0.59	-
PVPK90+0.5%CaCl ₂ +20%SPIR	-	-	1.67±0.69	-


356 **3.4. Physical characterization of the electrospun samples**



357
 358 **Figure 9. Differential scanning calorimetry thermograms (DSC) and X-ray powder diffraction patterns**
 359 **(XRPD) of (a-d) AC and C-AC electrospun PVPK90-based SPIR-loaded nanofibers, (e) PVPK90,**
 360 **(f) physical mixture of PVPK90 and 5% SPIR and (g) crystalline SPIR.**

361
 362 **3.5. Physical characterization**

363 In order to investigate the physical state of SPIR in the drug-loaded electrospun formulations
364 DSC measurements were carried out first (Fig. 10). The melting peak of the crystalline drug is
365 well observable around 210 °C in the curve of the pure crystalline SPIR and the 5% physical
366 mixture as well (Fig. 10f and g). In the cases of the drug-loaded electrospun samples no such
367 signs were detected suggesting the amorphization of SPIR, only the endothermic water loss of
368 PVPK90 can be seen between 50 °C and 100 °C (Fig. 10a–e). These results also confirm the
369 smooth operation of C-ACES regardless the much higher throughput rate applied compared to
370 ACES and conventional DCES. Additional measurements were recorded with XRPD, another
371 delicate method for identifying small traces of crystallinity. The sharp peaks of crystalline SPIR
372 is clearly visible, the most intense ones are at 8° and between 16° and 18° (Fig. 9f-g). PVPK90
373 as well as the drug-loaded samples were found to be amorphous. Thus, based on both the DSC
374 and XRPD measurements SPIR was dispersed in a fully amorphous form in the electrospun
375 formulations owing mainly to the fast drying effect of C-ACES and ACES.



376

377 **Figure 10. Raman maps illustrating the distribution of SPIR in (a) PVPK90-crystalline SPIR reference and**
 378 **(b) drug-loaded C-ACES fibers (1,200 mL/h, 100kV_{RMS}). Calculated SPIR content is illustrated by different**
 379 **colors in the maps from 0.0 (0%) to 1.0 (100%).**

380 Additional measurements were recorded with XRPD, another delicate method for identifying
 381 small traces of crystallinity. The sharp peaks of crystalline SPIR is clearly visible, the most
 382 intense ones are at 8° and between 16° and 18° (Fig. 10f and g). PVPK90 as well as the drug-
 383 loaded samples were found to be amorphous. Thus, based on both the DSC and XRPD
 384 measurements SPIR was dispersed in a fully amorphous form in the electrospun formulations
 385 owing mainly to the fast drying effect of C-ACES and ACES.

386

387 Raman mapping analyses were carried out in order to demonstrate the homogeneity of the drug
388 in the fibrous sample produced by C-ACES at high feeding rate (1200 mL/h). Raman
389 microspectroscopy is also an excellent method for identifying small traces of crystalline SPIR
390 because specific peaks of the crystalline and amorphous API distinctly differ (Patyi et al., 2010).
391 A casted PVPK90 + 20%SPIR film served as reference containing drug crystals since SPIR
392 tends to crystallize when the evaporation of the solvent is too slow. In Fig. 11a the
393 inhomogeneous distribution of SPIR is well observable in the casted film reference. The
394 brighter areas on the map represent nearly 100% SPIR content where the specific peak of
395 crystalline SPIR at 1690 cm⁻¹ appeared in the Raman spectra. In contrast, all the drug-loaded
396 electrospun samples showed homogeneous distribution of SPIR based on the Raman results
397 (Fig. 11b). The merging of the peak at 1690 cm⁻¹ with the adjacent peak signifies amorphous
398 SPIR content in the samples. To sum it up, Raman mapping revealed homogenous distribution
399 and amorphous SPIR content in the drug-loaded fibers in good accordance with the DSC and
400 XRPD measurements (Fig. 12).


401 *In vitro dissolution tests*

402 In order to explore the drug release from the electrospun samples in vitro dissolution tests were
403 carried out. Only half of the 25 mg dose dissolved from the crystalline SPIR reference after two
404 hours indicating limited solubility. All the electrospun fibers showed enhanced drug release, in
405 the case of the electrospun fibers with SDS the release was complete within 5 min. The ACES
406 and C-ACES samples exhibited equally fast dissolution.

407 Further fibrous samples were prepared and tested to examine the importance of SDS during the
408 enhanced dissolution of SPIR. When SDS was replaced with NH₄OAc or CaCl₂ in the AC
409 electrospun fibers for conductivity adjustment, SPIR concentration slowly peaked at 75% after
410 90 min. This phenomenon is similar to what Vigh et al. experienced with amorphous SPIR-
411 loaded PVP webs (Vigh et al., 2013). Accordingly, SPIR immediately crystallizes from PVP

412 formulations in the absence of a surfactant or complexing agent due to temporary gelation and
413 therefore induced hindered drug diffusion. Thus, besides determining conductivity, SDS also
414 prevents SPIR from precipitation during dissolution.

415 Based on these findings regarding the role of SDS one could wonder whether the fast drug
416 release of SPIR can be attributed only to the solubilizing effect and the huge surface area and
417 the amorphous form are less important. Therefore, the dissolution of the physical mixture of
418 the optimal composition used in the ACES and C-ACES experiments
419 (PVPK90 + 4%SDS + 20%SPIR) was also measured. In this case the dissolution reached again
420 only 75% after two hours in spite of the applied SDS. This verifies the importance of large
421 surfaces and amorphous state of the drug regarding dissolution.



422
423 **Figure 11. Dissolution profiles of SPIR from drug-loaded, PVPK90-based AC electrospun fibers (as spun)**
424 **containing 20% SPIR. The error bars indicate the standard deviations (n = 3) [25 mg dose, 900 mL pH = 6.8**
425 **100 mM phosphate buffer, USP Dissolution Apparatus 2 (paddle), 100 rpm, 37°C].**

426

427 **4. Conclusion**

428 The poor processability of PVPK90 with ACES was addressed via a thorough
429 optimization of conductivity and polymer concentration of the spinning solution. Similarly to
430 our earlier findings conductivity was found to be an important factor for ACES in the case of
431 PVPK90. As a result, excellent quality fibrous material could be AC electrospun with
432 submicronic diameters. With the optimized composition an attempt was made to scale up
433 electrospinning. By replacing the needle to a 110 mm rotating corona spinneret C-ACES was
434 able to achieve two orders of magnitude higher productivity compared to single needle DCES
435 and a 10-fold and a 20-fold increase compared to C-DCES and ACES, respectively. Drug-
436 loaded fibers were also successfully prepared with C-ACES at scaled-up productivity
437 maintaining similar fiber morphology to that of DCES and ACES. The physical state of the
438 drug was investigated with DSC and XRPD, SPIR was dispersed in an amorphous state in the
439 PVPK90 matrix in all the drug-loaded fibrous formulations. Raman mapping revealed that SPIR
440 was embedded homogenously in the fibrous samples, no traces of crystallinity could be detected
441 either. Based on fiber diameter analysis no difference could be observed between ACES and C-
442 ACES reference fibers despite the several times higher throughput of the corona spinneret.
443 When SPIR was added together with SDS the reduction of fiber diameter could be observed. In
444 turn, applying CaCl₂ or NH₄OAc with SPIR resulted in the thickening of the fibers compared
445 to the reference samples. In vitro dissolution studies showed ultrafast drug release in the case
446 of PVPK90-SDS-SPIR ACES and C-ACES samples. A suspected precipitation occurred with
447 CaCl₂ and NH₄OAc-loaded samples. These results indicate a double role of SDS: it increases
448 the conductivity of the electrospinning solution and hinders the precipitation of SPIR in the
449 dissolution media due to its solubilization ability. In summary, a new method was constructed
450 for a two orders of magnitude scale-up of conventional electrospinning with C-ACES also
451 capable to produce fibrous drug-loaded ASDs.

452 **5. Acknowledgements**

453 This work was supported by the National Research Development and Innovation in the frame
454 of FIEK_16-1-2016-0007 (Higher Education and Industrial Cooperation Center) project.
455 Supported by OTKA 121051, ÚNKP-18-3, ÚNKP-18-4-BME-95. New National Excellence
456 Program of the Ministry of Human Capacities and the János Bolyai Research Scholarship of
457 the Hungarian Academy of Sciences. Supported by Gedeon Richter's Talentum Foundation.

458 **References**

- 459 Angkawinitwong, U., Awwad, S., Khaw, P.T., Brocchini, S., Williams, G.R., 2017. Electrospun
460 formulations of bevacizumab for sustained release in the eye. *Acta Biomater.* 64, 126–136.
461 <https://doi.org/10.1016/j.actbio.2017.10.015>
- 462 Balogh, A., Cselkó, R., Démuth, B., Verreck, G., Mensch, J., 2015a. Alternating current
463 electrospinning for preparation of fibrous drug delivery systems. *Int. J. Pharm.* 495, 75–
464 80. <https://doi.org/10.1016/j.ijpharm.2015.08.069>
- 465 Balogh, A., Domokos, A., Farkas, B., Farkas, A., Rapi, Z., Kiss, D., Nyiri, Z., Eke, Z., Szarka,
466 G., Örkényi, R., Mátravölgyi, B., Faigl, F., Marosi, G., Nagy, Z.K., 2018. Continuous end-
467 to-end production of solid drug dosage forms: Coupling flow synthesis and formulation
468 by electrospinning. *Chem. Eng. J.* 350, 290–299. <https://doi.org/10.1016/j.cej.2018.05.188>
- 469 Balogh, A., Drávavölgyi, G., Faragó, K., Farkas, A., Vigh, T., Sóti, P.L., Wagner, I., Madarász,
470 J., Pataki, H., Marosi, G., Nagy, Z.K., 2014. Plasticized drug-loaded melt electrospun
471 polymer mats: Characterization, thermal degradation, and release kinetics. *J. Pharm. Sci.*
472 103, 1278–1287. <https://doi.org/10.1002/jps.23904>
- 473 Balogh, A., Farkas, B., Faragó, K., Farkas, A., Wagner, I., Van Assche, I., Verreck, G., Nagy,
474 Z.K., Marosi, G., 2015b. Melt-blown and electrospun drug-loaded polymer fiber mats for
475 dissolution enhancement: A comparative study. *J. Pharm. Sci.* 104, 1767–1776.

476 <https://doi.org/10.1002/jps.24399>

477 Balogh, A., Farkas, B., Pálvölgyi, Á., Domokos, A., Démuth, B., Marosi, G., Nagy, Z.K., 2017.
478 Novel alternating current electrospinning of hydroxypropylmethylcellulose acetate
479 succinate (HPMCAS) nanofibers for dissolution enhancement: The importance of
480 solution conductivity. *J. Pharm. Sci.* 106, 1634–1643.
481 <https://doi.org/10.1016/j.xphs.2017.02.021>

482 Balogh, A., Farkas, B., Verreck, G., Mensch, J., Borbás, E., Nagy, B., Marosi, G., Nagy, Z.K.,
483 2016. AC and DC electrospinning of hydroxypropylmethylcellulose with polyethylene
484 oxides as secondary polymer for improved drug dissolution. *Int. J. Pharm.*
485 <https://doi.org/10.1016/j.ijpharm.2016.03.024>

486 Borbás, E., Balogh, A., Bocz, K., Müller, J., Kiserdei, É., Vigh, T., Sinkó, B., Marosi, A.,
487 Halász, A., Dohányos, Z., Szenté, L., Balogh, G.T., Nagy, Z.K., 2015. In vitro dissolution-
488 permeation evaluation of an electrospun cyclodextrin-based formulation of aripiprazole
489 using μ FluxTM. *Int. J. Pharm.* 491, 180–189. <https://doi.org/10.1016/j.ijpharm.2015.06.019>

490 Borbás, E., Nagy, Z.K., Nagy, B., Balogh, A., Farkas, B., Tsinman, O., Tsinman, K., Sinkó, B.,
491 2018. The effect of formulation additives on in vitro dissolution-absorption profile and in
492 vivo bioavailability of telmisartan from brand and generic formulations. *Eur. J. Pharm.*
493 *Sci.* 114, 310–317. <https://doi.org/10.1016/j.ejps.2017.12.029>

494 Farkas, B., Balogh, A., Farkas, A., Domokos, A., Borbás, E., Marosi, G., Nagy, Z.K., 2018.
495 Medicated straws based on electrospun solid dispersions. *Period. Polytech. Chem. Eng.*
496 62, 310–316. <https://doi.org/10.3311/PPch.11931>

497 Frank, K.J., Westedt, U., Rosenblatt, K.M., Hölig, P., Rosenberg, J., Mägerlein, M., Fricker,
498 G., Brandl, M., 2014. What is the mechanism behind increased permeation rate of a poorly
499 soluble drug from aqueous dispersions of an amorphous solid dispersion? *J. Pharm. Sci.*

500 103, 1779–1786. <https://doi.org/10.1002/jps.23979>

501 Hirsch, E., Nacsá, M., Ender, F., Mohai, M., Nagy, Z.K., Marosi, G.J., 2018. Preparation and
502 Characterization of Biocompatible Electrospun Nanofiber Scaffolds. *Period. Polytech.*
503 *Chem. Eng.* 62, 1–9. <https://doi.org/10.3311/PPch.12854>

504 Hörter, D., Dressman, J.B., 2001. Influence of physicochemical properties on dissolution of
505 drugs in the gastrointestinal tract. *Adv. Drug Deliv. Rev.* 46, 75–87.
506 [https://doi.org/10.1016/S0169-409X\(00\)00130-7](https://doi.org/10.1016/S0169-409X(00)00130-7)

507 Jermain, S. V, Brough, C., Williams, R.O., 2018. Amorphous solid dispersions and nanocrystal
508 technologies for poorly water- soluble drug delivery - An update. *Int. J. Pharm.* 535, 379–
509 392. <https://doi.org/10.1016/j.ijpharm.2017.10.051>

510 Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., Onoue, S., 2011. Formulation design for
511 poorly water-soluble drugs based on biopharmaceutics classification system: Basic
512 approaches and practical applications. *Int. J. Pharm.* 420, 1–10.
513 <https://doi.org/10.1016/j.ijpharm.2011.08.032>

514 Kostakova, E.K., Meszaros, L., Maskova, G., Blazkova, L., Turcsan, T., Lukas, D., 2017.
515 Crystallinity of Electrospun and Centrifugal Spun Polycaprolactone Fibers: A
516 Comparative Study. *J. Nanomater.* 2017, 1–9. <https://doi.org/10.1155/2017/8952390>

517 Li, H., Zhang, L.-L., Zhang, Y.Y., Yu, D.-G., 2017. Core-shell medicated nanoparticles
518 prepared using coaxial electrospray for fast dissolution of paracetamol. *J. Investig. Med.*
519 65, A2. <https://doi.org/10.1136/jim-2017-MEBabstracts.5>

520 Liu, Z.P., Zhang, Y.Y., Yu, D.-G., Wu, D., Li, H.L., 2018. Fabrication of sustained-release zein
521 nanoparticles via modified coaxial electrospraying. *Chem. Eng. J.* 334, 807–816.
522 <https://doi.org/10.1016/j.cej.2017.10.098>

523 Lukáš, D., Sarkar, A., Martinová, L., Vodsed'áľková, K., Lubasová, D., Chaloupek, J., Pokorný,
524 P., Mikeš, P., Chvojka, J., Komárek, M., 2009. Physical principles of electrospinning
525 (electrospinning as a nano-scale technology of the twenty-first century). Text. Prog. 41,
526 59–140. <https://doi.org/10.1080/00405160902904641>

527 Marosi, G., Hirsch, E., Bocz, K., Toldy, A., Szolnoki, B., Bodzay, B., Csontos, I., Farkas, A.,
528 Balogh, A., Démuth, B., Nagy, Z.K., Pataki, H., 2018. Pharmaceutical and
529 Macromolecular Technologies in the Spirit of Industry 4.0 62, 457–466.
530 <https://doi.org/10.3311/PPch.12870>

531 **Molnár K., Nagy Zs.K., Marosi Gy, Mészáros L. Electrospinning spinneret and modified**
532 **electrospinning method for producing nanofibers in productive ways. Hungarian patent**
533 **P1200677 Budapest, Hungary (2012).**

534 Molnar, K., Nagy, Z.K., 2016. Corona-electrospinning: Needleless method for high-throughput
535 continuous nanofiber production. Eur. Polym. J. 74, 279–286.
536 <https://doi.org/10.1016/j.eurpolymj.2015.11.028>

537 Nagy, Z.K., Balogh, A., Démuth, B., Pataki, H., Vigh, T., Szabó, B., Molnár, K., Schmidt, B.T.,
538 Horák, P., Marosi, G., Verreck, G., Assche, I. Van, Brewster, M.E., 2015. High speed
539 electrospinning for scaled-up production of amorphous solid dispersion of itraconazole.
540 Int. J. Pharm. 480, 137–142. <https://doi.org/10.1016/j.ijpharm.2015.01.025>

541 Nagy, Z.K., Balogh, A., Drávavölgyi, G., Ferguson, J., Pataki, H., Vajna, B., Marosi, G., 2013.
542 Solvent-free melt electrospinning for preparation of fast dissolving drug delivery system
543 and comparison with solvent-based electrospun and melt extruded systems. J. Pharm. Sci.
544 102, 508–517. <https://doi.org/10.1002/jps.23374>

545 Nagy, Z.K., Balogh, A., Vajna, B., Farkas, A., Patyi, G., Kramarics, Á., György, M., 2012.
546 Comparison of electrospun and extruded Soluplus®-based solid dosage forms of improved

547 dissolution 101, 322–332. <https://doi.org/10.1002/jps>

548 Nagy, Z.K., Nyúl, K., Wagner, I., Molnár, K., Marosi, G., 2010. Electrospun water soluble
549 polymer mat for ultrafast release of donepezil HCL. *Express Polym. Lett.* 4, 763–772.
550 <https://doi.org/10.3144/expresspolymlett.2010.92>

551 Patyi, G., Bódis, A., Antal, I., Vajna, B., Nagy, Z., Marosi, G., 2010. Thermal and spectroscopic
552 analysis of inclusion complex of spironolactone prepared by evaporation and hot melt
553 methods. *J. Therm. Anal. Calorim.* 102, 349–355. [https://doi.org/10.1007/s10973-010-](https://doi.org/10.1007/s10973-010-0936-0)
554 [0936-0](https://doi.org/10.1007/s10973-010-0936-0)

555 Persano, L., Camposeo, A., Tekmen, C., Pisignano, D., 2013. Industrial upscaling of
556 electrospinning and applications of polymer nanofibers : A Review. *Macromol. Mater.*
557 *Eng.* 298, 504–520. <https://doi.org/10.1002/mame.201200290>

558 Pokorny, P., Kostakova, E., Sanetnik, F., Mikes, P., Chvojka, J., Kalous, T., Bilek, M., Pejchar,
559 K., Valtera, J., Lukas, D., 2014. Effective AC needleless and collectorless electrospinning
560 for yarn production. *Phys. Chem. Chem. Phys.* 16, 26816–26822. <https://doi.org/10.1039/C4cp04346d>

562 Škrlec, K., Zupančič, Š., Prpar Mihevc, S., Kocbek, P., Kristl, J., Berlec, A., 2019. Development
563 of electrospun nanofibers that enable high loading and long-term viability of probiotics.
564 *Eur. J. Pharm. Biopharm.* <https://doi.org/10.1016/j.ejpb.2019.01.013>

565 Theron, S.A., Yarin, A.L., Zussman, E., Kroll, E., 2005. Multiple jets in electrospinning:
566 Experiment and modeling. *Polymer (Guildf.)* 46, 2889–2899.
567 <https://doi.org/10.1016/j.polymer.2005.01.054>

568 Vasconcelos, T., Sarmiento, B., Costa, P., 2007. Solid dispersions as strategy to improve oral
569 bioavailability of poor water soluble drugs. *Drug Discov. Today* 12, 1068–1075.

570 <https://doi.org/10.1016/j.drudis.2007.09.005>

571 Vigh, T., Horváthová, T., Balogh, A., Sóti, P.L., Drávavölgyi, G., Nagy, Z.K., Marosi, G., 2013.
572 Polymer-free and polyvinylpyrrolidone-based electrospun solid dosage forms for drug
573 dissolution enhancement. *Eur. J. Pharm. Sci.* 49, 595–602.
574 <https://doi.org/10.1016/j.ejps.2013.04.034>

575 Yu, D.-G., Li, J.-J., Williams, G.R., Zhao, M., 2018. Electrospun amorphous solid dispersions
576 of poorly water-soluble drugs: A review. *J. Control. Release* 292, 91–110.
577 <https://doi.org/10.1016/j.jconrel.2018.08.016>

578 Yu, D.-G., Zheng, X.L., Yang, Y., Li, X.Y., Williams, G.R., Zhao, M., 2019. Immediate release
579 of helicid from nanoparticles produced by modified coaxial electro spraying. *Appl. Surf.*
580 *Sci.* 473, 148–155. <https://doi.org/10.1016/j.apsusc.2018.12.147>

581 Zupančič, Š., Preem, L., Kristl, J., Putrinš, M., Tenson, T., Kocbek, P., Kogermann, K., 2018a.
582 Impact of PCL nanofiber mat structural properties on hydrophilic drug release and
583 antibacterial activity on periodontal pathogens. *Eur. J. Pharm. Sci.* 122, 347–358.
584 <https://doi.org/10.1016/j.ejps.2018.07.024>

585 Zupančič, Š., Rijavec, T., Lapanje, A., Petelin, M., Kristl, J., Kocbek, P., 2018b. Nanofibers
586 with Incorporated Autochthonous Bacteria as Potential Probiotics for Local Treatment of
587 Periodontal Disease. *Biomacromolecules* 19, 4299–4306.
588 <https://doi.org/10.1021/acs.biomac.8b01181>